These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 18946842

  • 1. Selecting and controlling API crystal form for pharmaceutical development--strategies and processes.
    Yin SX, Grosso JA.
    Curr Opin Drug Discov Devel; 2008 Nov; 11(6):771-7. PubMed ID: 18946842
    [Abstract] [Full Text] [Related]

  • 2. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.
    Ticehurst MD, Marziano I.
    J Pharm Pharmacol; 2015 Jun; 67(6):782-802. PubMed ID: 25677227
    [Abstract] [Full Text] [Related]

  • 3. Crystal polymorphism in chemical process development.
    Lee AY, Erdemir D, Myerson AS.
    Annu Rev Chem Biomol Eng; 2011 Jun; 2():259-80. PubMed ID: 22432619
    [Abstract] [Full Text] [Related]

  • 4. Active pharmaceutical ingredient (API) production involving continuous processes--a process system engineering (PSE)-assisted design framework.
    Cervera-Padrell AE, Skovby T, Kiil S, Gani R, Gernaey KV.
    Eur J Pharm Biopharm; 2012 Oct; 82(2):437-56. PubMed ID: 22820647
    [Abstract] [Full Text] [Related]

  • 5. Solid form screening--a review.
    Aaltonen J, Allesø M, Mirza S, Koradia V, Gordon KC, Rantanen J.
    Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
    [Abstract] [Full Text] [Related]

  • 6. Phase transformation considerations during process development and manufacture of solid oral dosage forms.
    Zhang GG, Law D, Schmitt EA, Qiu Y.
    Adv Drug Deliv Rev; 2004 Feb 23; 56(3):371-90. PubMed ID: 14962587
    [Abstract] [Full Text] [Related]

  • 7. Applications of process analytical technology to crystallization processes.
    Yu LX, Lionberger RA, Raw AS, D'Costa R, Wu H, Hussain AS.
    Adv Drug Deliv Rev; 2004 Feb 23; 56(3):349-69. PubMed ID: 14962586
    [Abstract] [Full Text] [Related]

  • 8. Analysis of solid-state transformations of pharmaceutical compounds using vibrational spectroscopy.
    Heinz A, Strachan CJ, Gordon KC, Rades T.
    J Pharm Pharmacol; 2009 Aug 23; 61(8):971-88. PubMed ID: 19703341
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The role of cocrystals in pharmaceutical science.
    Shan N, Zaworotko MJ.
    Drug Discov Today; 2008 May 23; 13(9-10):440-6. PubMed ID: 18468562
    [Abstract] [Full Text] [Related]

  • 11. Quantification of crystalline forms in active pharmaceutical ingredient and tablets by X-ray powder diffraction.
    Cooper VB, Pearce GE, Petts CR.
    J Pharm Pharmacol; 2003 Sep 23; 55(9):1323-9. PubMed ID: 14604477
    [Abstract] [Full Text] [Related]

  • 12. Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid.
    Chen AM, Ellison ME, Peresypkin A, Wenslow RM, Variankaval N, Savarin CG, Natishan TK, Mathre DJ, Dormer PG, Euler DH, Ball RG, Ye Z, Wang Y, Santos I.
    Chem Commun (Camb); 2007 Jan 28; (4):419-21. PubMed ID: 17220990
    [Abstract] [Full Text] [Related]

  • 13. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
    Petzoldt C, Bley O, Byard SJ, Andert D, Baumgartner B, Nagel N, Tappertzhofen C, Feth MP.
    Eur J Pharm Biopharm; 2014 Apr 28; 86(3):337-50. PubMed ID: 24075979
    [Abstract] [Full Text] [Related]

  • 14. A Process Analytical Technology (PAT) approach to control a new API manufacturing process: development, validation and implementation.
    Schaefer C, Clicq D, Lecomte C, Merschaert A, Norrant E, Fotiadu F.
    Talanta; 2014 Mar 28; 120():114-25. PubMed ID: 24468350
    [Abstract] [Full Text] [Related]

  • 15. Applications of NIR spectroscopy to monitoring and analyzing the solid state during industrial crystallization processes.
    Févotte G, Calas J, Puel F, Hoff C.
    Int J Pharm; 2004 Apr 01; 273(1-2):159-69. PubMed ID: 15010140
    [Abstract] [Full Text] [Related]

  • 16. The importance of characterizing the crystal form of the drug substance during drug development.
    Clas SD.
    Curr Opin Drug Discov Devel; 2003 Jul 01; 6(4):550-60. PubMed ID: 12951818
    [Abstract] [Full Text] [Related]

  • 17. Multi-scale flowsheet simulation of an integrated continuous purification-downstream pharmaceutical manufacturing process.
    Sen M, Chaudhury A, Singh R, John J, Ramachandran R.
    Int J Pharm; 2013 Mar 10; 445(1-2):29-38. PubMed ID: 23380627
    [Abstract] [Full Text] [Related]

  • 18. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N, de Matas M, Gavan PT, York P.
    Adv Drug Deliv Rev; 2007 Jul 30; 59(7):617-30. PubMed ID: 17597252
    [Abstract] [Full Text] [Related]

  • 19. Quantitative determination of solid-state forms of a pharmaceutical development compound in drug substance and tablets.
    Xie Y, Tao W, Morrison H, Chiu R, Jona J, Fang J, Cauchon N.
    Int J Pharm; 2008 Oct 01; 362(1-2):29-36. PubMed ID: 18588963
    [Abstract] [Full Text] [Related]

  • 20. An innovative floating gastro retentive dosage system: formulation and in vitro evaluation.
    Sauzet C, Claeys-Bruno M, Nicolas M, Kister J, Piccerelle P, Prinderre P.
    Int J Pharm; 2009 Aug 13; 378(1-2):23-9. PubMed ID: 19465095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.